Owkin AI
Owkin / owkin.com
AI company applying federated machine learning to healthcare data across hospital networks, enabling multi-institution AI model training without sharing patient data for drug discovery and clinical biomarker development.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
No
Open source
No
Platforms
2
Advertisement
What is Owkin AI?
Owkin is a Paris-based AI company applying federated learning to healthcare — enabling ML models to be trained across multiple hospital datasets without moving or centralising the raw patient data. Federated learning addresses the fundamental challenge of healthcare AI: patient data is siloed in hospital systems and cannot be shared due to privacy regulations, but AI models trained on single-institution data lack the statistical power and diversity needed for generalisation.
Federated learning infrastructure connects multiple hospital sites — sending the model to each hospital's data rather than sending the data to a central location. Each hospital trains the model locally on its data and shares only model updates (gradients) rather than patient records — enabling multi-institution model development without regulatory data sharing barriers.
Oncology AI applications are Owkin's primary focus — developing AI biomarkers from pathology images, genomic data, and clinical records that predict treatment response, survival outcomes, and drug efficacy. Pharmaceutical companies use Owkin's models for clinical trial patient selection and drug development.
Pathology AI analyses tissue biopsy images using computer vision to extract prognostic and predictive biomarkers — predicting which cancer patients will respond to specific treatments. Owkin's federated approach enables training on pathology data from many hospitals globally.
Biotech and pharmaceutical partnerships are Owkin's primary commercial model — partnering with major pharma companies (Sanofi, Servier, BMS) to apply federated AI to clinical trial data and drug development.
How Owkin AI works
Owkin AI runs as computer vision software built around image and data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Owkin AI.
Federated learning
Sends ML models to hospital data rather than moving data to central location — enabling multi-institution AI training while patient data never leaves individual hospital systems.
Oncology AI biomarkers
Develops prediction models for treatment response, survival outcomes, and drug efficacy from pathology, genomic, and clinical data across federated hospital networks.
Pharmaceutical partnership model
Collaborates with pharma companies to apply federated AI to drug development and clinical trial patient selection across hospital network data.
Best use cases
Who should use it
Pros
- Federated learning architecture solves the fundamental privacy barrier to multi-institution healthcare AI training
- Oncology focus provides deepest domain expertise for the highest-value healthcare AI application
- Sanofi, Servier, and BMS pharmaceutical partnerships validate commercial model
- Patient data never leaves hospital systems — strongest privacy architecture in multi-institution healthcare AI
Cons
- Highly specialised company — not a general AI platform for healthcare organisations
- Business model is primarily pharmaceutical partnership rather than accessible healthcare product
- Federated learning infrastructure requires hospital IT cooperation for deployment
Advertisement
Is it worth the price?
Enterprise licensing to pharmaceutical companies and research institutions. No public pricing. Paris-based. Contact for pricing.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Owkin AI
Flatiron Health (covered) provides real-world oncology data. Komodo Health (covered, rank 565) provides real-world health data analytics. PathAI (covered) provides pathology AI. Varian provides AI for oncology treatment planning.
Owkin AI vs Flatiron Health AI
A side-by-side look at the closest alternative in this category.
Owkin AI
Owkin
Flatiron Health AI
Flatiron Health (Roche)
Enterprise licensing to pharmaceutical companies and research institutions. No public pricing. Paris-based. Contact for pricing.
Enterprise licensing to pharmaceutical companies and cancer centres. No public pricing. Subsidiary of Roche.
GDPR compliant (French company, EU data). HIPAA eligible. ISO 27001. Research ethics approval. Enterprise data handling agreements. Federated architecture — patient data never leaves hospital systems.
HIPAA compliant with BAA. SOC 2 Type II. GDPR compliant for EU deployments. IRB approval for research datasets. FDA-accepted data quality standards.
Federated learning architecture ensures patient data remains within each hospital's systems. Only model gradient updates are shared — never raw patient data. Strongest privacy architecture for multi-institution healthcare AI.
Patient health data processed under strict HIPAA BAA and applicable research ethics frameworks. De-identification and IRB protocols govern research dataset access.
- Federated learning architecture solves the fundamental privacy barrier to multi-institution healthcare AI training
- Oncology focus provides deepest domain expertise for the highest-value healthcare AI application
- Sanofi, Servier, and BMS pharmaceutical partnerships validate commercial model
- Patient data never leaves hospital systems — strongest privacy architecture in multi-institution healthcare AI
- 9 million+ patient oncology database is one of the most comprehensive real-world oncology datasets available for pharmaceutical research
- FDA-accepted real-world evidence from multiple regulatory submissions provides unmatched regulatory validation
- NLP curation of clinical notes extracts structured data inaccessible through structured EHR data alone
- Roche ownership provides stability and pharmaceutical partnership pipeline
- Highly specialised company — not a general AI platform for healthcare organisations
- Business model is primarily pharmaceutical partnership rather than accessible healthcare product
- Federated learning infrastructure requires hospital IT cooperation for deployment
- Roche ownership creates potential conflict of interest concerns for pharmaceutical competitors as data partners
- Real-world evidence database access requires partnership agreements limiting accessibility
- Clinical note NLP accuracy requires ongoing validation — structured EHR data remains more reliable for some variables
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Owkin
Platforms
Web, API
Deployment
On-premise, Federated
Integrations
Hospital EHR systems, Pathology systems, Genomics platforms, Pharmaceutical systems, API
Team Collaboration
No
Launch Year
2021
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
GDPR compliant (French company, EU data). HIPAA eligible. ISO 27001. Research ethics approval. Enterprise data handling agreements. Federated architecture — patient data never leaves hospital systems.
Federated learning architecture ensures patient data remains within each hospital's systems. Only model gradient updates are shared — never raw patient data. Strongest privacy architecture for multi-institution healthcare AI.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Owkin AI and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Owkin AI
Editorial Verdict
Should you use Owkin AI?
Owkin is the leading federated learning AI company for pharmaceutical organisations wanting to train AI models across hospital networks without sharing patient data for drug discovery and oncology biomarker development.
Last verified July 24, 2026.